Hyperoxaluria – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hyperoxaluria – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Long-Term Safety and Efficacy Study of Nedosiran Injection for Patients with Primary Hyperoxaluria https://clinicaltrials.eu/trial/long-term-safety-and-efficacy-study-of-nedosiran-injection-for-patients-with-primary-hyperoxaluria/ Wed, 29 Apr 2026 15:01:19 +0000 https://clinicaltrials.eu/trial/long-term-safety-and-efficacy-study-of-nedosiran-injection-for-patients-with-primary-hyperoxaluria/ This clinical trial is focused on studying a rare condition called Primary Hyperoxaluria. This is a genetic disorder where the body produces too much oxalate, a substance that can lead to kidney stones and other serious kidney problems. The treatment being tested in this study is a medication called DCR-PHXC, which is given as a solution for injection under the skin. The purpose of the study is to evaluate the long-term safety and effectiveness of this treatment in patients with Primary Hyperoxaluria.

Participants in the study will receive regular injections of DCR-PHXC and will be monitored over time to see how the treatment affects their kidney function. This will be measured by looking at the estimated glomerular filtration rate, or eGFR, which is a test that shows how well the kidneys are working. The study will also track any side effects or changes in health that occur during the treatment period.

The study aims to provide valuable information on how DCR-PHXC can help manage Primary Hyperoxaluria and improve kidney health over the long term. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being. This research could lead to better treatment options for those affected by this challenging condition.

]]> Study on Lumasiran for Patients with Advanced Primary Hyperoxaluria Type 1 https://clinicaltrials.eu/trial/study-on-lumasiran-for-patients-with-advanced-primary-hyperoxaluria-type-1/ Wed, 29 Apr 2026 14:24:15 +0000 https://clinicaltrials.eu/trial/study-on-lumasiran-for-patients-with-advanced-primary-hyperoxaluria-type-1/ This clinical trial is focused on studying a rare genetic condition called Primary Hyperoxaluria Type 1 (PH1). PH1 is a disorder that causes the body to produce too much of a substance called oxalate, which can lead to kidney stones and other serious health problems. The trial is testing a new treatment called Lumasiran, also known by its code name ALN-GO1. Lumasiran is a solution for injection that is designed to reduce the levels of oxalate in the body.

The purpose of the study is to evaluate how effective and safe Lumasiran is for patients with advanced PH1. The study is divided into two groups: one group includes patients who are not on dialysis, and the other group includes patients who are on dialysis. Dialysis is a treatment that helps remove waste products from the blood when the kidneys are not working properly. The study will look at how Lumasiran affects the levels of oxalate in the blood over a period of several months.

Participants in the study will receive regular injections of Lumasiran and will have their blood oxalate levels monitored. The study will also assess other health aspects, such as kidney function and quality of life, to understand the overall impact of the treatment. The trial aims to provide valuable information about the potential benefits of Lumasiran for people living with PH1.

]]>